PLAINSBORO, N.J., Oct. 30, 2015 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART) today announced that its CUSA® Excel+ system is the first and only ultrasonic tissue ablation system cleared by the FDA for liver resection and tumor removal. Previously cleared for a wide variety of surgical applications, this new, specific indication demonstrates both Integra’s continued leadership in ultrasonic tissue ablation and its focus on safety and optimization in the operating room.
The CUSA Excel+ system improves efficiency in liver surgery for both laparoscopic and open surgical procedures, including the removal of benign or malignant tumors or other unwanted tissue, liver transplantation, living donor transplantation and pediatric liver surgery. Its proprietary technology promotes safety without sacrificing speed by helping the surgeon to maintain the integrity of critical blood vessels. The CUSA Excel+ system can help with lessening blood loss during liver procedures and might reduce the need for intraoperative blood transfusion. Additional benefits to the patient may include reduced length of procedure and reduced hospital stay.
“We are very excited to receive this new liver indication for our CUSA Excel+ system,” said Bob Davis, Integra’s Corporate Vice President, and President - Specialty Surgical Solutions. “This expanded indication represents another example of our commitment to offer surgeons safe and effective products that help them achieve the best outcome for their patients.”
Since 1977, the CUSA name has been associated with premium quality and innovation in ultrasonic ablation. CUSA systems have led the ultrasonic tissue ablation market for over 30 years, and are recognized worldwide for optimizing removal of fibrous and soft tissue.
Integra LifeSciences, a world leader in medical technology, is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2014 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Integra LifeSciences: Media Gianna Sabella 609-936-2389 firstname.lastname@example.org Investors: Angela Steinway 609-936-2268 email@example.com Michael Beaulieu 609-750-2827 firstname.lastname@example.org
Source:Integra LifeSciences Holdings Corporation